Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Olaparib in Advanced Cholangiocarcinoma (BIL-PPP)
NCT06441747Phase 2Recruiting
- Sponsor
- Australasian Gastro-Intestinal Trials Group
- Start
- Sep 2024
- Primary completion
- Aug 2026
- Modality
- Antibody Conjugates, Small Molecules, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, olaparib in cholangiocarcinoma (CCA), sponsored by Australasian Gastro-Intestinal Trials Group. Started Sep 2024; status: recruiting.
02
Drugs
durvalumabolaparib
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT06441747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441747.